How far have we reached in development of effective influenza vaccine?

References

• Fraaij PL, Heikkinen T. Seasonal influenza: the burden of disease in children. Vaccine 2011;29(43):7524–7528. doi:10.1016/j.vaccine.2011.08.010.
   PubMed Web of Science ®Google Scholar
• McElhaney J, Zhou X, Talbot H, et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza. Vaccine 2012;30(12):2060–2067. doi:10.1016/j.vaccine.2012.01.015.
   PubMed Web of Science ®Google Scholar
• Saunders-Hastings PR, Krewski D. Reviewing the history of pandemic influenza: understanding patterns of emergence and transmission. Pathogens 2016;5(4):66. doi:10.3390/pathogens5040066.
   PubMed Web of Science ®Google Scholar
• Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888–1897. doi:10.1056/NEJMoa1304459.
   PubMed Web of Science ®Google Scholar
• Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002;20(25–26):3068–3087. doi:10.1016/S0264-410X(02)00254-2.
   PubMed Web of Science ®Google Scholar
• Treanor JJ. Influenza viruses. In: Kaslow RA, Stanberry LR, Le Duc JW, editors. Viral infections of humans. Boston, MA: Springer; 2014. pp. 455–478.
   Google Scholar
• Francis T. Vaccination against influenza. Bull World Health Organ 1953;8(5–6):725–741.
   PubMedGoogle Scholar
• Kitchen LW, Vaughn DW. Role of US military research programs in the development of US-licensed vaccines for naturally occurring infectious diseases. Vaccine 2007;25(41):7017–7030. doi:10.1016/j.vaccine.2007.07.030.
   PubMed Web of Science ®Google Scholar
• Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention; 2010.
   Google Scholar
• Lang PO, Mendes A, Socquet J, et al. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging 2012;7:55. doi:10.2147/CIA.S25215.
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010;28(23):3929–3935. doi:10.1016/j.vaccine.2010.03.067.
   PubMed Web of Science ®Google Scholar
• Cheong HJ, Song JY, Heo JY, et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol. 2011;18(8):1358–1364. doi:10.1128%2FCVI.05111-11.
   PubMed Web of Science ®Google Scholar
• Gomez PL, Robinson JM, Rogalewicz JA. Vaccine manufacturing. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia, PA: WB Saunders Company; 2013. pp. 44–57.
   Google Scholar
• Kim HS. Mechanisms for the enhancement of influenza B virus vaccine antigen yield [Dissertation]. Australia: RMIT; 2012.
   Google Scholar
• Maassab HF. Adaptation and growth characteristics of influenza virus at 25 °C. Nature 1967;213(5076):612–614. doi:10.1038/213612a0.
   PubMed Web of Science ®Google Scholar
• Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm 2015;94:251–263. doi:10.1016/j.ejpb.2015.05.023.
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12(1):36–44. doi:10.1016/S1473-3099(11)70295-X.
   PubMed Web of Science ®Google Scholar
• Shinya K, Ebina M, Yamada S, Ono M, et al. Avian flu: influenza virus receptors in the human airway. Nature 2006;440(7083):435–436. doi:10.1038/440435a.
   PubMed Web of Science ®Google Scholar
• Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009;27(36):4953–4960. doi:10.1016/j.vaccine.2009.05.099.
   PubMed Web of Science ®Google Scholar
• Alexandrova GI, Budilovsky GN, Koval TA, et al. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine 1986;4(2):114–118. doi:10.1016/0264-410X(86)90049-6.
   PubMed Web of Science ®Google Scholar
• Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbio Rev 2013;26(3):476–492. doi:10.1128/CMR.00097-12.
   PubMed Web of Science ®Google Scholar
• McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012–2013: variable protection by age and virus type. J Infect Dis 2015;211(10):1529–1540. doi:10.1093/infdis/jiu647.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci USA 2017;114(47):12578–12583. doi:10.1073/pnas.1712377114.
   PubMed Web of Science ®Google Scholar
• Audsley JM, Tannock GA. Cell-based influenza vaccines. Drugs 2008;68(11):1483–1491. doi:10.2165/00003495-200868110-00002.
   PubMed Web of Science ®Google Scholar
• Genzel Y, Dietzsch C, Rapp E, et al. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. Appl Microbiol Biotechnol 2010;88(2):461–475. doi:10.1007/s00253-010-2742-9.
   PubMed Web of Science ®Google Scholar
• Pau MG, Ophorst C, Koldijk MH, et al. The human cell line PER. C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001;19(17–19):2716–2721. doi:10.1016/S0264-410X(00)00508-9.
   PubMed Web of Science ®Google Scholar
• Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER: C6® cell grown influenza H7 virus vaccine. Vaccine 2009;27(13):1889–1897. doi:10.1016/j.vaccine.2009.01.116.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Herbinger KH, et al. Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 2012;30(7):1388–1396. doi:10.1016/j.vaccine.2011.12.009.
   PubMed Web of Science ®Google Scholar
• Garcia-Sastre A, Palese P. Genetic manipulation of negative-strand RNA virus genomes. Annu Rev Microbiol 1993;47(1):765–790. doi:10.1146/annurev.mi.47.100193.004001.
   PubMedGoogle Scholar
• Zaman M, Ashraf S, Dreyer NA, Toovey S. Human infection with avian influenza virus, Pakistan, 2007. Emerg Infect Dis 2011;17(6):1056–1059. doi:10.3201/eid1706.091652.
   PubMed Web of Science ®Google Scholar
• Neumann G, Watanabe T, Ito H, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999;96(16):9345–9350. doi:10.1073/pnas.96.16.9345.
   PubMed Web of Science ®Google Scholar
• Hoffmann E, Neumann G, Kawaoka Y, et al. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000;97(11):6108–6113. doi:10.1073/pnas.100133697.
   PubMed Web of Science ®Google Scholar
• Neumann G, Fujii K, Kino Y, Kawaoka Y. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci USA 2005;102(46):16825–16829. doi: 10.1073/pnas.0505587102.
   PubMed Web of Science ®Google Scholar
• Zhang X, Kong W, Ashraf S, Curtiss R. A one-plasmid system to generate influenza virus in cultured chicken cells for potential use in influenza vaccine. J Virol 2009;83(18):8303–9296. doi:10.1128/JVI.00781-09.
   Web of Science ®Google Scholar
• Massin P, Rodrigues P, Marasescu M, et al. Cloning of the chicken RNA polymerase I promoter and use for reverse genetics of influenza A viruses in avian cells. J Virol 2005;79(21):13811–13816. doi:10.1128/JVI.79.21.13811-13816.2005.
   PubMed Web of Science ®Google Scholar
• Murakami S, Horimoto T, Nidom CA, et al. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. J Virol 2008;82(21):10502–10509. doi:10.1128/JVI.00970-08.
   PubMed Web of Science ®Google Scholar
• van Oers MM, Pijlman GP, Vlak JM. Thirty years of baculovirus – insect cell protein expression: from dark horse to mainstream technology. J Gen Virol 2015;96(Pt_1):6–23. doi:10.1099/vir.0.067108-0.
   PubMedGoogle Scholar
• Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine 2011;29(12):2272–2278. doi:10.1016/j.vaccine.2011.01.039.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011;29(44):7733–7739. doi:10.1016/j.vaccine.2011.07.128.
   PubMed Web of Science ®Google Scholar
• King JC, Jr, Cox MM, Reisinger K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months. Vaccine 2009;27(47):6589–6594. doi:10.1016/j.vaccine.2011.01.039.
   PubMed Web of Science ®Google Scholar
• Felberbaum RS. The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotech J 2015;10(5):702–714. doi:10.1002/biot.201400438.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Bu F, et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005;23(50):5751–5759. doi:10.1016/j.vaccine.2005.07.098.
   PubMed Web of Science ®Google Scholar
• Chen BJ, Leser GP, Morita E, Lamb RA. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 2007;81(13):7111–7123. doi:10.1128/JVI.00361-07.
   PubMed Web of Science ®Google Scholar
• Quan FS, Kim YC, Song JM, et al. Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clin Vaccine Immunol 2013;20(9):1433–1439. doi:10.1128/CVI.00251-13.
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007;25(19):3871–3878. doi:10.1016/j.vaccine.2007.01.106.
   PubMed Web of Science ®Google Scholar
• Pushko P, Pearce MB, Ahmad A, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 2011;29(35):5911–5918. doi:10.1016/j.vaccine.2011.06.068.
   PubMed Web of Science ®Google Scholar
• Mooney AJ, Li Z, Gabbard JD, et al. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice. J Virol 2013;87(1):363–371. doi:10.1128/JVI.02330-12.
   PubMed Web of Science ®Google Scholar
• Van Kampen KR, Shi Z, Gao P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005;23(8):1029–1036. doi:10.1016/j.vaccine.2004.07.043.
   PubMed Web of Science ®Google Scholar
• Shen X, Söderholm J, Lin F, et al. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. Vaccine 2012;30(48):6946–6954. doi:10.1016/j.vaccine.2012.02.071.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Hu Z, Gordon IJ, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012;19(11):1792–1797. doi:10.1128/CVI.05663-11.
   PubMed Web of Science ®Google Scholar
• Smith LR, Wloch MK, Ye M, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010;28(13):2565–2572. doi:10.1016/j.vaccine.2010.01.029.
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012;30(12):1210–1216. doi:10.1038/nbt.2436.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kawaoka Y, inventors; Wisconsin Alumni Research Foundation, assignee. Influenza M2 protein mutant viruses as live influenza attenuated vaccines. US patent 9474798B2; 2016.
   Google Scholar
• Slepushkin VA, Katz JM, Black RA, et al. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995;13(15):1399–1402. doi:10.1016/0264-410X(95)92777-Y.
   PubMed Web of Science ®Google Scholar
• El Bakkouri K, Descamps F, De Filette M, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011;186(2):1022–1031. doi:10.4049/jimmunol.0902147.
   PubMed Web of Science ®Google Scholar
• Fan J, Liang X, Horton MS, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004;22(23-24):2993–3003. doi:10.1016/j.vaccine.2004.02.021.
   PubMed Web of Science ®Google Scholar
• Turley CB, Rupp RE, Johnson C, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011;29(32):5145–5152. doi:10.1016/j.vaccine.2011.05.041.
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011;239(1):62–84. doi:10.1111/j.1600-065X.2010.00980.x.
   PubMed Web of Science ®Google Scholar
• Chu T, Tyznik AJ, Roepke S, et al. Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner. Cell Rep 2013;3(3):701–708. doi:10.1016/j.celrep.2013.02.020.
   PubMed Web of Science ®Google Scholar
• Crotty S. Follicular helper CD4 T cells (Tfh). Annu Rev Immunol 2011;29(1):621–663. doi:10.1146/annurev-immunol-031210-101400.
   PubMed Web of Science ®Google Scholar
• Assarsson E, Bui HH, Sidney J, et al. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 2008;82(24):12241–12251. doi:10.1128/JVI.01563-08.
   PubMed Web of Science ®Google Scholar
• Lee LYH, Simmons C, de Jong MD, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008;118(10):3478–3490. doi:10.1172/JCI32460.
   PubMed Web of Science ®Google Scholar
• Chen W, McCluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res 2006;95:203–247. doi:10.1016/S0065-230X(06)95006-4.
   PubMed Web of Science ®Google Scholar
• Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled phase I trial. Vaccine 2012;30(31):4655–4660. doi:10.1016/j.vaccine.2012.04.089.
   PubMed Web of Science ®Google Scholar
• Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a t-cell-based influenza vaccine, MVA-NP + M1, in humans. Clin Infect Dis 2012;55(1):19–25. doi:10.1093/cid/cis327.
   PubMed Web of Science ®Google Scholar